Notify me when M.D. Ph.D. David D. Chang files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | Common Stock | 5.2% | $16,578,676 | +$1,186,838 | 12,101,223 | +7.7% | David D. Chang, M.D., Ph.D. | 31 Dec 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|